StockWatch
·

Gujarat Fluorochemicals Ltd

BSE: 542812

P/L Snapshot

Q2 FY27 · standalone

vs Q1 FY27·vs Q2 FY26
Revenue
1.7K
+30.3%+49.8%
Expenditure
1.3K
+24.2%+47.2%
Net Profit
309.00
+53.7%+58.5%
OPM %
30.65%
+2.62pp-1.18pp

Shareholding

Pattern breakdown

P/L Trends

(in crores)

RevenueExpenditureNet Profit
0.00477.40954.801.4K1.9KQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Price Chart
Reports

Growth beats fluoropolymer guide, but battery losses and capex delays mask the picture

fluoropolymer · battery materials · capex execution

Result verdictFollow-upQ2 FY2706 Nov 20266 minMetals & Mining

Strong topline growth masks battery losses; execution risk on capex delays

fluoropolymer beat · battery scaling · margin stable

TranscriptDeep diveQ2 FY2706 Nov 20266 minMetals & Mining

GFL Q2 FY27: Consolidated PAT +42% YoY to ₹240 Cr, margin holds near 27%, tops Street view

specialty chemicals · fluoropolymer · ev battery materials

ResultsQ2 FY2703 Nov 20263 minMetals & Mining
Latest
Quarterly Result3 Nov, 2:13 pm

GFL Q2 FY27: Consolidated PAT +42% YoY to ₹240 Cr, margin holds near 27%, tops Street view

Gujarat Fluorochemicals' consolidated Q2 FY27 print clears the bar the Street set going in. Revenue came in at ₹1,760 Cr against a pre-result expectation of ₹1,500–1,550 Cr, and consolidated PAT of ₹240 Cr beat the ₹200–230 Cr range analysts had pencilled in (per our pre-result preview, citing S&P Global/TipRanks/SimplyWall.st consensus). The bigger surprise is on margins: EBITDA of ₹473 Cr works out to a 26.9% margin, comfortably above the 20–22% the Street was bracing for after Q1's margin miss, and essentially flat against Q1's 27.0% — so the 'margin recovery' question our preview posed is better read as margin stabilization than a sharp rebound. Consolidated basic EPS was ₹22.11 (standalone ₹28.12). The headline YoY PAT growth needs a caveat. On a reported basis PAT is up 42% from the year-ago quarter's restated ₹169 Cr; our stored year-ago record of ₹179 Cr (EPS ₹16.31) is the figure as originally reported, before this filing's Note 4 restated it down by ₹10 Cr after the EV Products subsidiary reversed a ₹24 Cr deferred-tax asset and reclassified ₹22 Cr of capital work-in-progress. Against that originally-reported base, YoY PAT growth reads closer to 34%. Either way, growth is driven by the core Chemicals segment, where revenue rose 43% YoY to ₹1,743 Cr and EBITDA to ₹505 Cr; margins there are still down from a year ago (consolidated EBITDA margin 26.9% vs 29.6% in Q2 FY26), consistent with the cost pressure the preview flagged. A new ₹7 Cr fair-value loss on the EV subsidiary's Series A CCPS also sat in this quarter's finance costs — strip it out and PBT would be closer to ₹346 Cr versus the reported ₹339 Cr. On guidance, the filing doesn't break out fluoropolymer-specific volumes, so the 17–20% annual fluoropolymer growth target reaffirmed at the Q1 call can't be directly graded this quarter. The EV Products segment, management's other guided marker, posted ₹41 Cr of revenue (up from ₹29 Cr in Q1) with the EBITDA loss widening to -₹32 Cr from -₹30 Cr — still well short of the 3-digit-crore quarterly revenue management has guided for Q4 FY27, though two quarters remain. H1 consolidated capex (cash, including CWIP movements) of ₹841 Cr tracks toward but is still well under a third of the ₹3,100 Cr FY27 target (₹2,300 Cr EV, ₹800 Cr chemicals) management laid out, implying a much heavier H2 spend. No management press release or commentary accompanied this filing, so there is no fresh management quote to check against the numbers. Separately, the company confirmed the ILFL–IHIL–GFCL demerger/amalgamation scheme remains with regulators (NOC received July 2026, implementation steps pending) — unrelated to this quarter's P&L. EV Products segment assets more than doubled YoY to ₹3,286 Cr (from ₹1,762 Cr) against segment liabilities of ₹1,390 Cr (from ₹220 Cr), reflecting the capex build-out the Series A CCPS and subsidiary borrowings are funding.

3 Nov 2026, 02:13 pm

Corporate Events

Board MeetingFLUOROCHEM
2026
3Nov

Board Meeting

The meeting of the Board of Directors of the Company is sche…

BSE Filing ↗
Board MeetingFLUOROCHEM
2026
24Sep

Board Meeting

The Eighth Annual General Meeting of the Company will be hel…

BSE Filing ↗
DividendFLUOROCHEM
2026
17Sep

₹3 / share

BSE Filing ↗
Board MeetingFLUOROCHEM
2026
12Aug

Board Meeting

The meeting of the Board of Directors of the Company is sche…

BSE Filing ↗
Board MeetingFLUOROCHEM
2026
26May

Board Meeting

The board meeting is scheduled to consider and approve the A…

BSE Filing ↗
DividendFLUOROCHEM
2025
22Sep

₹3 / share

BSE Filing ↗
Board MeetingFLUOROCHEM
2024
29Oct

Board Meeting

Consider, approve and take on record the Unaudited Standalon…

BSE Filing ↗
DividendFLUOROCHEM
2024
20Sep

₹3 / share

BSE Filing ↗
Board MeetingFLUOROCHEM
2024
7Feb

Board Meeting

Consider and approve Intimation of Board Meeting, Unaudited …

BSE Filing ↗
Board MeetingFLUOROCHEM
2023
3Nov

Board Meeting

Intimation of Board Meeting, consider and approve Unaudited …

BSE Filing ↗
DividendFLUOROCHEM
2023
22Sep

₹2 / share

BSE Filing ↗